Clinical benefit in BRAFV600 mutation-positive melanoma defined by programmed death ligand 1 (PD-L1) and/or lactate dehydrogenase (LDH) status: Exploratory analyses from the IMspire150 study

PA Ascierto, C Robert, K Lewis, R Gutzmer, D Stroyakovskiy, HJ Gogas, S Protsenko, RP Pereira, T Eigentler, P Rutkowski, L Demidov, G Moiseevich Manikhas, V McNally, H Forbes, K Shah, Y Yan, G McArthur